Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thyroid adenoma-associated protein (THADA)
- Target
- THADA
- Molecular classification
- Other (protein with armadillo repeats; not a classical receptor, enzyme, transporter, or transcription factor but involved in protein-protein interactions and tRNA modification regulation)
01
Overview
Thyroid adenoma-associated protein (THADA) is a cytoplasmic, armadillo repeat-containing protein encoded by the THADA gene. It localizes primarily to the endoplasmic reticulum where it interacts with and modulates sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA), influencing calcium signaling and energy metabolism. In complex with FTSJ1, it also regulates tRNA (32-2'-O)-methylation[1][3]. Disruptions of the THADA gene—through chromosomal aberrations, SNPs, or oncogenic fusions—are implicated in benign and malignant thyroid neoplasms and are associated with altered metabolic profiles, predisposition to obesity, and type 2 diabetes[1][2][3][4][5]. Fusions involving THADA, such as THADA-IGF2BP3, serve as a biomarker for some thyroid tumors, though THADA itself is not currently a direct pharmacological target and its therapeutic modulation poses metabolic and oncogenic challenges.
- Other names
- THADA armadillo repeat containingtRNA (32-2'-O)-methyltransferase regulator THADAGITAKIAA1767FLJ21877ARMC13Trm732gene inducing thyroid adenomas proteinthyroid adenoma-associated proteinTrm732 homologdeath receptor-interacting protein
02
Biological functions
Regulation of energy metabolism (via endoplasmic reticulum calcium signaling)Modulator of apoptosis and death receptor pathwayRegulation of tRNA methylation (with FTSJ1)
03
Disease associations
Cancer (benign thyroid adenomas, follicular variant papillary thyroid carcinoma, lung cancer, hepatocellular carcinoma, type 2 diabetes, polycystic ovary syndrome)Metabolic diseases (obesity, type 2 diabetes)
04
Safety considerations
Potential for low specificity: THADA fusion-positive thyroid malignancies are typically low risk but may prompt surgery in nodules that are not aggressiveLimited functional annotation; consequences of manipulating tRNA modification pathway or calcium metabolism are unknown and may impact systemic energy balance and apoptosis
05
Biomarkers
THADA-IGF2BP3 fusion (biomarker for thyroid tumors/thyroid carcinoma and non-invasive follicular thyroid neoplasm with papillary-like nuclear features)Genomic rearrangements, SNPs for risk stratification in metabolic syndromes and diabetes
Beyond the preview
Go deeper on Thyroid adenoma-associated protein (THADA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thyroid adenoma-associated protein (THADA).